Terapet
Geneva
About Terapet
Terapet SA, a Geneva-based spin-off from CERN, specializes in advanced nuclear imaging technologies aimed at enhancing the precision and safety for cancer treatment. Their flagship product, Qual╬│scan, is a real-time, non-invasive quality assurance device for proton therapy, currently in the commercialization phase. Additionally, they are developing Nuclyscan, a next-generation total-body PET scanner designed for theranostic applications, with plans for deployment in 2026.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.3M
- Funding stage: Seed
- Last round: Grant (Mar 2024)
- Website: terapet.ch
- Phone: [email protected]
Industries & Categories
Health Care, Oncology
Social Profiles
Canonical: https://fsome.com/organization/terapet-10007 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.